Malaria is common in areas such as Africa, South America, and Southern Asia. This medicine is not effective against all strains of malaria. Folic acid and hydroxychloroquine dosing sle Hydroxychloroquine plaquenil adverse effects Correction The text describing a single-arm skin cancer study evaluating trametinib plus Novartis’s BRAF inhibitor dabrafenib with the addition of hydroxychloroquine for patients. Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma BAMM The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib together with hydroxychloroquine may work better in treating patients with pancreatic cancer. Taking hydroxychloroquine long-term or at high doses may cause irreversible damage to the retina of your eye. Hydroxychloroquine is also an antirheumatic medicine and is used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. Trametinib hydroxychloroquine Phase Ib/II study of hydroxychloroquine in combination., Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced. Methotrexate vs plaquenilBlood test for plaquenilOcular side effects from plaquenilAutophagic flux assay chloroquineChloroquine ovarian cancer Trametinib and Hydroxychloroquine in Treating Patients with Pancreatic Cancer THREAD University of Utah / Novartis Pharmaceuticals Identifier NCT03825289 Trametinib PubChem CID 11707110 Huntsman Cancer Institute, University of Utah Photo National Cancer Institute Investigators at the Huntsman Cancer Institute at the University of Utah are conducting a Phase I clinical. Phase I Study of Trametinib and Hydroxychloroquine in.. Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic.. Trametinib and Hydroxychloroquine in Treating Patients.. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and / or dabrafenib may lower the chance of brain tumors from growing or spreading compared to usual treatments. Location 3 locations This phase I / II trial studies the side effects and best dose of hydroxychloroquine when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IV melanoma that has spread to other places in the body. Abstract. Pancreatic ductal adenocarcinoma PDAC is a recalcitrant disease responsible for ~43,000 deaths in the USA in 2017. Despite an advanced understanding of the genetics, biochemistry and biology of pancreatic cancer, there is no effective pathway-targeted therapy for PDAC such that the standard of care treatment for most patients remains conventional cytotoxic chemotherapy.